Loading grant details…
Digital Melt Curve Analysis Platform for Longitudinal Cancer Patient Monitoring
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Combinati, Inc. |
| Country | United States |
| Start Date | Apr 01, 2021 |
| End Date | May 11, 2021 |
| Duration | 40 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10256226 |
Grant Description
Abstract Building on its commercially available Absolute Q digital PCR platform, during the 24-month Phase 2 SBIR project, Combinati will complete the development of the first Digital Melt Curve Analysis (DMCA) platform to the market to further advance the adoption of digital genomics for highly accurate, sensitive and reproducible nucleic acid quantification for longitudinal patient monitoring.
To provide the ?whole product? solution and prove the function, we will demonstrate the DMCA platform with Luminex?s 11- plex ESR1 (Estrogen Receptor 1) assay and conduct Beta testing at Dana Farber Cancer Institute: 1. Three beta instruments and the analysis software capable of digital melt curve analysis. 2.
Complete dMCA validation internally with commercially available melt calibration kits. 3. Demonstrate
All Grantees
Combinati, Inc.
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
